ALBO Berita Valas

Albireo Pharma Posts Positive Topline Results From Phase 3 Study Of Bylvay In Alagille Syndrome

Albireo Pharma, Inc. (ALBO) announced Tuesday positive topline results from the Phase 3 ASSERT study evaluating the safety and efficacy of Bylvay in Alagille syndrome (ALGS) patients from birth to early adulthood.

RTTNews | 1043 days ago

Terms | Privacy | Site Map | Site Map Calendar

HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.

EURUSD	1.16745	GBPUSD	1.35184	AUDUSD	0.64835
USDJPY	147.649	USDCAD	1.38195	USDCHF	0.80607